Intravitreal dexamethasone implant Ozurdex® in naive and refractory patients with different subtypes of diabetic macular edema

被引:56
作者
Castro-Navarro, Veronica [1 ,2 ]
Cervera-Taulet, Enrique [1 ]
Navarro-Palop, Catalina [1 ]
Monferrer-Adsuara, Clara [1 ]
Hernandez-Bel, Laura [1 ]
Montero-Hernandez, Javier [1 ]
机构
[1] Univ Gen Hosp Valencia, Ave Tres Cruces S-N, Valencia 46015, Spain
[2] Ophthalmol Dept, Ave Tres Cruces S-N, Valencia 46015, Spain
关键词
Diabetes; Macular edema; Corticoids; Dexamethasone implant; Ozurdex; COHERENCE TOMOGRAPHIC PATTERNS; VASCULAR LEAKAGE; BEVACIZUMAB; EFFICACY; SAFETY; LEUKOSTASIS; THICKNESS; INJECTION;
D O I
10.1186/s12886-018-1022-9
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
BackgroundDiabetic macular edema (DME) can be treated with different alternatives, among them Dexamethasone intravitreal implant 0.7mg (DEX 0.7) has demonstrated that may improve both central macular thickness (CMT) and best corrected visual acuity (BCVA). This study aimed to evaluate the effect of the intravitreal dexamethasone implant Ozurdex (R) in patients with different subtypes of diabetic macular edema over a 6-month follow-up period.MethodsEighty-four (29 naive and 55 previously treated) eyes were included in this retrospective study. For each patient, the BCVA [Early Treatment Diabetic Retinopathy Study (ETDRS) charts] and macular thickness on optical coherence tomography (OCT) at baseline visit and within the 2nd, 4th, and 6th months of follow-up were obtained. The main outcomes measurements were the mean change in BCVA and in CMT with respect to the baseline value. The percentage of patients gaining 5 letters and10 letters in BCVA was also analyzed. Results: A total of 84 eyes, 29 (34.5%) naive and 55 (65.5%) non-naive, from 69 patients were included in the study. BCVA at baseline was 58.8 (16.4) and 61.8 (11.6) in naive and refractory patients, respectively, p=0.4513. At every visit, BCVA significantly improved from baseline in naive and non-naive eyes (p<0.0001 and p=0.0003, respectively; Friedman rank sum test). At baseline, the mean CMT was 466.2 (189.7) m and 448.1 (110.7) m in the naive and non-naive patients, respectively (p=0.5830); and decreased to 339.3 (92.5) m and 357.5 (79.1) m, respectively (p=0.0004 and p<0.0001, respectively, Wilcoxon signed-rank test). The proportion of patients gaining 10 letters was significantly greater in the naive group, p=0.0199.ConclusionThe intravitreal dexamethasone implant (Ozurdex) is effective for the treatment of diabetic macular edema, even in refractory cases that have failed to respond to previous therapies.
引用
收藏
页数:8
相关论文
共 38 条
[1]   Longitudinal Study of Sustained-Release Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema [J].
Aknin, Isabelle ;
Melki, Laurent .
OPHTHALMOLOGICA, 2016, 235 (04) :187-188
[2]   Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study [J].
Augustin, Albert J. ;
Kuppermann, Baruch D. ;
Lanzetta, Paolo ;
Loewenstein, Anat ;
Li, Xiao-Yan ;
Cui, Harry ;
Hashad, Yehia ;
Whitcup, Scott M. .
BMC OPHTHALMOLOGY, 2015, 15
[3]   Diabetic Macular Edema: Pathogenesis and Treatment [J].
Bhagat, Neelakshi ;
Grigorian, Ruben A. ;
Tutela, Arthur ;
Zarbin, Marco A. .
SURVEY OF OPHTHALMOLOGY, 2009, 54 (01) :1-32
[4]   Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema [J].
Boyer, David S. ;
Yoon, Young Hee ;
Belfort, Rubens, Jr. ;
Bandello, Francesco ;
Maturi, Raj K. ;
Augustin, Albert J. ;
Li, Xiao-Yan ;
Cui, Harry ;
Hashad, Yehia ;
Whitcup, Scott M. .
OPHTHALMOLOGY, 2014, 121 (10) :1904-1914
[5]   DEXAMETHASONE INTRAVITREAL IMPLANT FOR TREATMENT OF DIABETIC MACULAR EDEMA IN VITRECTOMIZED PATIENTS [J].
Boyer, David S. ;
Faber, David ;
Gupta, Sunil ;
Patel, Sunil S. ;
Tabandeh, Homayoun ;
Li, Xiao-Yan ;
Liu, Charlie C. ;
Lou, Jean ;
Whitcup, Scott M. .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2011, 31 (05) :915-923
[6]   Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials RISE and RIDE [J].
Brown, David M. ;
Quan Dong Nguyen ;
Marcus, Dennis M. ;
Boyer, David S. ;
Patel, Sunil ;
Feiner, Leonard ;
Schlottmann, Patricio G. ;
Rundle, Amy Chen ;
Zhang, Jiameng ;
Rubio, Roman G. ;
Adamis, Anthony P. ;
Ehrlich, Jason S. ;
Hopkins, J. Jill .
OPHTHALMOLOGY, 2013, 120 (10) :2013-2022
[7]   Comparison of the Effect of Intravitreal Dexamethasone Implant in Vitrectomized and Nonvitrectomized Eyes for the Treatment of Diabetic Macular Edema [J].
Cevik, Sadik Gorkem ;
Yilmaz, Sami ;
Cevik, Mediha Tok ;
Akalp, Fatma Duriye ;
Avci, Remzi .
JOURNAL OF OPHTHALMOLOGY, 2018, 2018
[8]   Pharmacokinetics and Pharmacodynamics of a Sustained-Release Dexamethasone Intravitreal Implant [J].
Chang-Lin, Joan-En ;
Attar, Mayssa ;
Acheampong, Andrew A. ;
Robinson, Michael R. ;
Whitcup, Scott M. ;
Kuppermann, Baruch D. ;
Welty, Devin .
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2011, 52 (01) :80-86
[9]   Dexamethasone implant in diabetic macular edema in real-life situations [J].
Chhablani, J. ;
Bansal, P. ;
Veritti, D. ;
Sambhana, S. ;
Sarao, V. ;
Pichi, F. ;
Carrai, P. ;
Massaro, D. ;
Lembo, A. ;
Mansour, A. M. ;
Banker, A. ;
Gupta, S. R. ;
Hamam, R. ;
Lanzetta, P. .
EYE, 2016, 30 (03) :426-430
[10]   Diagnosis of Macular Edema [J].
Cunha-Vaz, Jose ;
Coscas, Gabriel .
OPHTHALMOLOGICA, 2010, 224 :2-7